Abstract
Background/Aims: To estimate the cost utility (cost per QALY) of screening for hepatitis C (HCV) infection in people attending genito-urinary medicine clinics in England.
Methods: An epidemiological model of screening and diagnosis was combined with a Markov chain model of treatment with combination therapy to estimate cost utility. Parameters for the model were informed by literature review, expert opinion and a survey of current screening practice.
Results: The base case estimate was about pound85,000 per QALY. Selective screening is more cost effective. If screening is restricted to only 20% or 10% of attenders, cost utility is estimated as pound39,647 and pound34,288 per QALY. If screening is restricted only to those with a history of injecting drug use, cost utility would be pound27,138 per QALY. Estimates are particularly sensitive to acceptance rates for screening and treatment.
Conclusions: Universal screening for HCV in GUM clinics is unlikely to be cost effective. There is limited evidence to support screening of people other than those with a history of injecting drug use and even this policy should be considered with some care and in the context of further research. (C) 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 814-825 |
| Number of pages | 11 |
| Journal | Journal of Hepatology |
| Volume | 39 |
| DOIs | |
| Publication status | Published - 2003 |
Keywords
- cost utility
- hepatitis C
- epidemiological model
- VIRUS-INFECTION
- RISK-FACTORS
- DRUG-USERS
- SEXUAL TRANSMISSION
- INTERFERON-ALPHA
- SEMINAL FLUID
- LIVER-BIOPSY
- HCV RNA
- SEMEN
- RIBAVIRIN
